Patients on IBD biologics at no extra risk from COVID-19, suggest studies
Patients with IBD being treated with TNF inhibitors appear to be at no increased risk of requiring ventilation or dying if they contract COVID-19, a study suggests.
Despite the immune-modulating drugs being linked to a higher risk of other severe infections, reassuring preliminary results from a multinational database of COVID-19 outcomes suggest they could even have a protective effect.
The data from the SECURE-IBD database covered 525 patients in 33 countries, of whom 161 were hospitalised and 16 died.
Systemic corticosteroid use